Treatment I + Treatment II + Treatment III
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active Rheumatoid Arthritis
Conditions
Active Rheumatoid Arthritis
Trial Timeline
Nov 1, 2015 → Jun 1, 2018
NCT ID
NCT02534896About Treatment I + Treatment II + Treatment III
Treatment I + Treatment II + Treatment III is a phase 3 stage product being developed by Sun Pharmaceutical for Active Rheumatoid Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02534896. Target conditions include Active Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Active Rheumatoid Arthritis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02534896 | Phase 3 | Terminated |
Competing Products
20 competing products in Active Rheumatoid Arthritis